Press

Psyence Group Announces Resignation of Board Member

Nov 20 • 2 min read

Psyence Group Inc. (CSE:PSYG) (“Psyence” or the “Company”), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing announced today that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company…

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

Nov 20 • 5 min read

– Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – – Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Professor, Chief Neurologist, DMSc, Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Denmark…

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance

Nov 20 • 3 min read

As part of the Company’s plan for recompliance, the Company’s shareholders approved a reverse stock split on November 14, 2023. Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced receipt of a Staff…

FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement

Nov 20 • 3 min read

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company“), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that, further to its press release dated November 7, 2023, that its distribution date for the contemplated plan of arrangement (the “Arrangement“) is November 29, 2023 (the “Distribution…

Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC

Nov 16 • 4 min read

Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia (“Court”) has today made orders approving the scheme of arrangement in relation to the Company’s proposed re-domiciliation from Australia to the United States (“Scheme”), under which Incannex Healthcare Inc. (“Holdco”) will become the ultimate…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441